CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 2, 2015, Pages 165-173

  Kadakia, Aditi ^a   Rajan, Suja S ^a,b   Abughosh, Susan ^a   Du, Xianglin L ^b   Johnson, Michael L ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

5 Fluorouracil; breast cancer; chemotherapy; Cyclophosphamide; Methotrexate

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; ANTINEOPLASTIC AGENT; CISPLATIN;

AGED; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; COMORBIDITY; CONFERENCE PAPER; DRUG UTILIZATION; EDUCATIONAL STATUS; ETHNICITY; FEMALE; HUMAN; LONGITUDINAL STUDY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MARRIAGE; MEDICARE; PATIENT PREFERENCE; BREAST NEOPLASMS; CANCER REGISTRY; CLINICAL PRACTICE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; MEDICARE; METHOTREXATE; PHYSICIAN'S PRACTICE PATTERNS; SEER PROGRAM; UNITED STATES;

EID: 84926407643     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31828f5b01     Document Type: Conference Paper

References (47)

1. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007;25:3871-3876.
2. Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750.
3. Giordano SH, Hortobagyi GN, Kau SW, et al. Breast cancer treatment guidelines in older women. J Clin Oncol. 2005;23:783-791.
4. Muss HB. The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women. Cancer. 1994;74:2165-2171.
5. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet. 1998;352:930-942.
6. NCCN Clinical Practice Guidelines in Oncology version I.2012. Available at: http://www.nccn.com. Accessed June 6, 2011.
7. NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA. 1991;265:391-395.
8. Blum JL, Jones SE, Fay JW, et al. Guidelines for systemic therapy of early stage breast cancer. Breast Cancer Res Treat. 1997;43: 259-276.
9. Levine M, Moutquin JM, Walton R, et al. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiatives Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ. 2001;164: 1681-1690.
10. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19:1455-1461.
11. Du XL, Key CR, Osborne C, et al. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138:90-97.
12. Harlan LC, Abrams J, Warren JL, et al. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol. 2002;20:1809-1817.
13. Du X, Goodwin JS. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer. 2001;92:730-737.
14. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: The results of 20 years of follow-up. N Engl J Med. 1995;332:901-906.
15. Harlan LC, Clegg LX, Abrams J, et al. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol. 2006;24:872-877.
16. Giordano SH, Duan Z, Kuo YF, et al. Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst. 2006;98:382-388.
17. Shen Y, Dong W, Feig BW, et al. Patterns of treatment for earlystage breast cancers in M. D. Anderson Cancer Center from 1997 to 2004. Cancer. 2009;115:2041-2051.
18. Giordano SH, Lin YL, Kuo YF, et al. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012;30:2232-2239.
19. FDA Drug approval Package: Taxol (Paclitaxel)NDA # NDA 20- 262/S 024. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/20262s024.cfm. Accessed July 20, 2012.
20. FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108788.htm. Accessed July 20, 2012.
21. FDA Drug approval Package: Nolvadex (Tamoxifen citrate) NDA # 17-970/S039/S040. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/98/17970S39S40.cfm. Accessed July 20, 2012.
22. FDA Drug approval Package: Arimidex (Anastrozole) NDA # NDA 20-541/S10. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/20-541S006-Arimidex.cfm. Accessed January 10, 2013.
23. FDA Drug approval Package: Aromasin (Exemestane) NDA # NDA 20-753/S10. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/99/20-753-Aromasin.cfm. Accessed January 10, 2013.
24. FDA Drug approval Package: Letrozole (Femara) NDA # NDA 20-726/S006. Available at: http://www.accessdata.fda.gov/drug satfda-docs/nda/2001/20-726S006-Femara.cfm. Accessed January 10, 2013.
25. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Chemotherapy and hormonal therapy for early breast cancer. Lancet. 2005;365:1687-1717.
26. Carpenter JT, Velez-Garcia E, Aron BS, et al. Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (adriamycin) and fluorouracil (CAF) versus cyclophosphamide, methotrexate and fluorouracil (CMF) in node positive breast cancer: A Southeastern Cancer Study Group study. Proc Am Soc Clin Oncol. 1994;13 (Abstr 66).
27. Bergh J, Jonsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 2001;40:253-281.
28. Martin M, Villar A, Sole-Calvo A, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group. Ann Oncol. 2003;14:833-842.
29. Verrill M. Chemotherapy for early-stage breast cancer: A brief history. Br J Cancer. 2009;101(suppl 1):S2-S5.
30. National Cancer Institute. The SEER Program Code Manual. Revised. Bethesda, MD: NCI; 1994.
31. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
32. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl 8):IV-3-IV-18.
33. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
34. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEERMedicare data to identify chemotherapy use. Med care. 2002;40(suppl 8):IV-55-IV-61.
35. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(suppl 8):IV-104-IV-117.
36. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079.
37. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data an overview. Med care. 2002;40(suppl 8):IV-26-IV-35.
38. Schilsky RL. Renal and metabolic toxicities of cancer treatment. In: Perry MC, Yarbro JW, eds. Toxicity of Chemotherapy: Clinical Oncology Monographs. Orlando, FL: Grune & Stratton; 1984:576.
39. Hurria AK, Brogan KS, Panageas C, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2005;92:151-156.
40. Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A populationbased study. J Clin Oncol. 2005;23:8597-8605.
41. Pinder MC, Duan Z, Goodwin J, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808-3815.
42. Du XL, Xia R, Chin Liu C, et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009;115:5296-5308.
43. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet. 2012;379:432-444.
44. Barni S, Cabiddu M, Petrelli F. Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls. Expert Rev Anticancer Ther. 2010;10:185-198.
45. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Clarke M, Coates AS. Adjuvant chemotherapy in oestrogenreceptor- poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371:29-40.
46. Du XL, Lairson DR, Begley CE, et al. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. J Clin Oncol. 2005;23: 8620-8628.
47. Wennberg JE, Fisher ES, Goodman DC, et al. Tracking the care of patients with severe chronic illness. The Dartmouth Atlas of Health Care. The Dartmouth Institute; 2008. Available at: http://www.dartmouthatlas.org/. Accessed March 23, 2013.